The Custom Pharmaceutical Services (CPS) facility of Dr Reddy’s Laboratories Ltd at its Technology Development Centre (TDC-1), Miyapur here has cleared the US Food and Drug Administration (USFDA) audit.

The audit of the facility "has been completed today with zero observations'',’ the Hyderabad-based company informed the bourses in an update on Thursday.

The company has also received an Establishment Inspection Report (EIR) from the USFDA for its formulation Srikakulum plant (SEZ) unit - II, Andhra Pradesh, according to the update.

Dr Reddy’s scrip was trading up by 7.11 per cent at Rs 2,478 on the BSE.